Objective . To improve the treatment of tumors, we studied the combined effects of docetaxel and batimastat (BB 94) on mouse forestomach carcinoma (MFC), and compared them with doxorubicin. Methods and results. In vit...Objective . To improve the treatment of tumors, we studied the combined effects of docetaxel and batimastat (BB 94) on mouse forestomach carcinoma (MFC), and compared them with doxorubicin. Methods and results. In vitro, growth curve analysis, MTT assay and clonogenic assay used to determine the cytotoxic effect of docetaxel or/and BB 94 on MFC cell showed that docetaxel but not BB 94 had a significant cytotoxicity, and the effect of docetaxel wasn’t enhanced by BB 94. In early stage MFC tumor model, obvious antitumor effect of docetaxel or doxorubicin given i.v. at maximum tolerated dose (MTD, docetaxel: 20mg/kg; doxorubicin: 6mg/kg) every 4 days for 3 injections (q4d×3), even that of BB 94 (30mg/kg i.p. qd×20) was observed. Tumor growth inhibition was greater for docetaxel batimastat (96.0%) than for doxorubicin-batimastat (88.0%), docetaxel (89.0%), doxorubicin (68.0%) and BB 94 (33.0%), and the effect of docetaxel could be potentiated by BB 94. Docetaxel also showed activity against advanced stage MFC tumor in dose-dependent manner, and was more effective at MTD than doxorubicin with 4/5 regressions, 46.5 days tumor growth delay and 2.8log10 tumor cell kill. Conclusion. Our results suggest that in the MFC model with dose and schedule used, docetaxel is an effective cytotoxic new drug against MFC tumor and BB 94 enchances the antitumor activity of docetaxel.展开更多
Objective:To study the inhibitory effect of docetaxel(DOC),oxaliplatin(OXA) and their combination on proliferation of cervical cancer line HeLa.Methods:Cell morphological changes were observed by inverted phase contra...Objective:To study the inhibitory effect of docetaxel(DOC),oxaliplatin(OXA) and their combination on proliferation of cervical cancer line HeLa.Methods:Cell morphological changes were observed by inverted phase contrast microscope,cell inhibition rates in different groups were examined by MTT,and cell cycle and apoptosis rates were determined by flow cytometry(FCM).Results:DOC and OXA inhibited the proliferation of cervical cancer cell line HeLa in a dose-dependent,and combination of the two drugs had an enhanced inhibitory effect;the apoptosis rate was also significantly increased when the two drugs were used in combination.Conclusion:DOC and OXA can synergistically inhibit the proliferation of cervical cancer cell line HeLa,which indicates that combination of the two drugs might has a promising future for clinical treatment of cervical cancer.展开更多
文摘Objective . To improve the treatment of tumors, we studied the combined effects of docetaxel and batimastat (BB 94) on mouse forestomach carcinoma (MFC), and compared them with doxorubicin. Methods and results. In vitro, growth curve analysis, MTT assay and clonogenic assay used to determine the cytotoxic effect of docetaxel or/and BB 94 on MFC cell showed that docetaxel but not BB 94 had a significant cytotoxicity, and the effect of docetaxel wasn’t enhanced by BB 94. In early stage MFC tumor model, obvious antitumor effect of docetaxel or doxorubicin given i.v. at maximum tolerated dose (MTD, docetaxel: 20mg/kg; doxorubicin: 6mg/kg) every 4 days for 3 injections (q4d×3), even that of BB 94 (30mg/kg i.p. qd×20) was observed. Tumor growth inhibition was greater for docetaxel batimastat (96.0%) than for doxorubicin-batimastat (88.0%), docetaxel (89.0%), doxorubicin (68.0%) and BB 94 (33.0%), and the effect of docetaxel could be potentiated by BB 94. Docetaxel also showed activity against advanced stage MFC tumor in dose-dependent manner, and was more effective at MTD than doxorubicin with 4/5 regressions, 46.5 days tumor growth delay and 2.8log10 tumor cell kill. Conclusion. Our results suggest that in the MFC model with dose and schedule used, docetaxel is an effective cytotoxic new drug against MFC tumor and BB 94 enchances the antitumor activity of docetaxel.
文摘Objective:To study the inhibitory effect of docetaxel(DOC),oxaliplatin(OXA) and their combination on proliferation of cervical cancer line HeLa.Methods:Cell morphological changes were observed by inverted phase contrast microscope,cell inhibition rates in different groups were examined by MTT,and cell cycle and apoptosis rates were determined by flow cytometry(FCM).Results:DOC and OXA inhibited the proliferation of cervical cancer cell line HeLa in a dose-dependent,and combination of the two drugs had an enhanced inhibitory effect;the apoptosis rate was also significantly increased when the two drugs were used in combination.Conclusion:DOC and OXA can synergistically inhibit the proliferation of cervical cancer cell line HeLa,which indicates that combination of the two drugs might has a promising future for clinical treatment of cervical cancer.
